Published in J Card Fail on February 01, 2003
Predictors of early mortality in implantable cardioverter-defibrillator recipients. Europace (2009) 1.55
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol (2007) 1.52
Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol (2014) 1.48
Adaptation and maladaptation of the heart in obesity. Hypertension (2008) 1.29
Adherence to the WCRF/AICR guidelines for cancer prevention is associated with lower mortality among older female cancer survivors. Cancer Epidemiol Biomarkers Prev (2013) 1.25
Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle (2011) 1.22
The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer (2013) 1.17
Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle (2010) 1.10
Origin of symptoms in chronic heart failure. Heart (2005) 1.10
Prolonged exposure to high dietary lipids is not associated with lipotoxicity in heart failure. J Mol Cell Cardiol (2009) 1.09
Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. Eur J Heart Fail (2010) 0.99
Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry. Int J Obes (Lond) (2017) 0.96
The obesity paradox in men versus women with systolic heart failure. Am J Cardiol (2012) 0.95
Obesity is associated with left atrial enlargement, E/A reversal and left ventricular hypertrophy. Exp Clin Cardiol (2008) 0.95
Complications of obesity in adults: a short review of the literature. Malawi Med J (2014) 0.94
Recent trends in the characteristics and prognosis of patients hospitalized with acute heart failure. Clin Epidemiol (2011) 0.91
The partial pressure of resting end-tidal carbon dioxide predicts major cardiac events in patients with systolic heart failure. Am Heart J (2008) 0.89
Prognostic implications of relations of left ventricular systolic dysfunction with body composition and myocardial energy expenditure: the Strong Heart Study. J Am Soc Echocardiogr (2007) 0.88
Impact of obesity on quality of life and depression in patients with heart failure. Eur J Heart Fail (2006) 0.87
Is there a reversal in the effect of obesity on mortality in old age? J Aging Res (2011) 0.87
Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One (2011) 0.85
Pro-HEART - a randomized clinical trial to test the effectiveness of a high protein diet targeting obese individuals with heart failure: rationale, design and baseline characteristics. Contemp Clin Trials (2013) 0.83
Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure? Heart Fail Rev (2014) 0.83
Nutrition in Pediatric Cardiomyopathy. Prog Pediatr Cardiol (2007) 0.81
A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region. BMC Cardiovasc Disord (2014) 0.80
Anatomy of the obesity paradox in heart failure. Heart Fail Rev (2014) 0.80
Body mass index, treatment practices, and mortality in patients with acute heart failure. Coron Artery Dis (2009) 0.80
Development of a murine model of early sepsis in diet-induced obesity. Biomed Res Int (2014) 0.79
Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol (2013) 0.79
Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Exp Ther Med (2014) 0.78
Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. Clin Res Cardiol (2014) 0.78
Malnutrition and associated factors among heart failure patients on follow up at Jimma university specialized hospital, Ethiopia. BMC Cardiovasc Disord (2015) 0.78
Prognostic significance of the pN classification supplemented by body mass index for esophageal squamous cell carcinoma. Thorac Cancer (2015) 0.78
Association between the body mass index and the clinical findings in patients with acute heart failure: evaluation of the obesity paradox in patients with severely decompensated acute heart failure. Heart Vessels (2016) 0.77
Prognostic value of systolic short-term blood pressure variability in systolic heart failure. Clin Hypertens (2016) 0.75
Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. J Am Heart Assoc (2016) 0.75
Changes in body composition in patients with left ventricular systolic dysfunction initiated on beta-blocker therapy. Exp Clin Cardiol (2007) 0.75
Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure - A Pilot Study. J Obes Weight Loss Ther (2012) 0.75
Obesity paradox in heart failure: a heavy matter. ESC Heart Fail (2016) 0.75
Obesity paradox in heart failure: statistical artifact, or impetus to rethink clinical practice? Heart Fail Rev (2017) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Age-dependent relationships between body mass index and mortality: Singapore longitudinal ageing study. PLoS One (2017) 0.75
Positive Effect of Higher Adult Body Mass Index on Overall Survival of Digestive System Cancers Except Pancreatic Cancer: A Systematic Review and Meta-Analysis. Biomed Res Int (2017) 0.75
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Frailty consensus: a call to action. J Am Med Dir Assoc (2013) 6.54
Cachexia: a new definition. Clin Nutr (2008) 5.49
What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol (2014) 5.39
Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol (2011) 4.99
Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. EuroIntervention (2013) 4.30
Increased metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol (1985) (2007) 4.02
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 3.89
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol (2012) 3.87
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Fractional flow reserve-guided revascularization: practical implications of a diagnostic gray zone and measurement variability on clinical decisions. JACC Cardiovasc Interv (2013) 3.49
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation (2009) 3.05
Ethical authorship and publishing. Int J Cardiol (2008) 2.97
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. Eur Heart J (2005) 2.84
Test-retest repeatability of cardiopulmonary exercise test variables in patients with cardiac or respiratory disease. Eur J Prev Cardiol (2014) 2.75
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr (2006) 2.67
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery. Heart (2013) 2.61
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2012) 2.60
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc (2010) 2.55
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation (2006) 2.44
Arterial pulse wave dynamics after percutaneous aortic valve replacement: fall in coronary diastolic suction with increasing heart rate as a basis for angina symptoms in aortic stenosis. Circulation (2011) 2.34
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol (2005) 2.28
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol (2010) 2.25
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Hybrid iFR-FFR decision-making strategy: implications for enhancing universal adoption of physiology-guided coronary revascularisation. EuroIntervention (2013) 2.15
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol (2003) 2.12
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 2.10
Real-time dynamic carbon dioxide administration: a novel treatment strategy for stabilization of periodic breathing with potential application to central sleep apnea. J Am Coll Cardiol (2010) 2.09
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail (2005) 2.06
Top of the charts: download versus citations in the International Journal of Cardiology. Int J Cardiol (2005) 2.06
Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle (2010) 2.04
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med (2005) 1.99
Multinational evaluation of the interpretability of the iterative method of optimisation of AV delay for CRT. Int J Cardiol (2012) 1.93
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Statement on authorship and publishing ethics in the International Journal of Cardiology. Int J Cardiol (2011) 1.90
Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol (2012) 1.90
An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle (2010) 1.89
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail (2009) 1.88
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86